|
US6548643B1
(en)
|
1994-11-16 |
2003-04-15 |
Austin Research Institute |
Antigen carbohydrate compounds and their use in immunotherapy
|
|
US8021667B2
(en)
|
1994-11-16 |
2011-09-20 |
Macfarlane Burnet Institute For Medical Research And Public Health Ltd |
Compositions for immunotherapy and uses thereof
|
|
WO1997010845A1
(en)
*
|
1995-09-18 |
1997-03-27 |
Board Of Trustees Of The University Of Illinois |
An immunostimulant and antineoplastic glycan obtained from mycobacterium vaccae
|
|
AUPN568095A0
(en)
*
|
1995-09-27 |
1995-10-26 |
Austin Research Institute, The |
Anti-Galalpha(1,3)Gal antibody binding peptides
|
|
US20080286228A1
(en)
*
|
1995-10-20 |
2008-11-20 |
Tarantolo Stefano R |
Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
|
|
CA2232344C
(en)
*
|
1995-10-20 |
2005-04-05 |
University Of Nebraska Board Of Regents |
Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
|
|
EP0849275A1
(de)
*
|
1996-09-26 |
1998-06-24 |
Rijksuniversiteit te Leiden |
Mannosylierte Peptide
|
|
ES2273376T3
(es)
*
|
1996-12-20 |
2007-05-01 |
MERCK & CO., INC. |
Formulaciones de vacunas recombinantes frente a papilomas.
|
|
CU22629A1
(es)
*
|
1997-03-06 |
2000-12-22 |
Ct Ingenieria Genetica Biotech |
Formulaciones inmunopotenciadoras para uso vacunal
|
|
DE19740357A1
(de)
*
|
1997-09-13 |
1999-03-18 |
Martin Wilhelm |
Phosphoryliertes Zuckermolekül
|
|
DE69840578D1
(de)
*
|
1997-09-29 |
2009-04-02 |
Macfarlane Burnet Inst For Med |
Mannose-rezeptor tragende zellinie und antigen zusammensetzung
|
|
JP2001518556A
(ja)
*
|
1997-10-03 |
2001-10-16 |
ガレニカ ファーマシューティカルズ, インコーポレイテッド |
イミン形成ポリサッカライド、その調製、ならびにアジュバントおよび免疫刺激剤としてのその使用
|
|
EP1574217A1
(de)
*
|
1997-10-03 |
2005-09-14 |
Galenica Pharmaceuticals, Inc. |
Iminbildende Polysaccharide, deren Herstellung und Verwendung als Zusatzmittel und Immunstimulierende Mittel
|
|
DE19758400A1
(de)
*
|
1997-12-30 |
1999-07-01 |
Max Delbrueck Centrum |
Tumorvakzine für MUC1-positive Karzinome
|
|
AU2903999A
(en)
*
|
1998-03-12 |
1999-09-27 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
|
|
US6573245B1
(en)
*
|
1998-04-28 |
2003-06-03 |
Galenica Pharmaceuticals, Inc. |
Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
|
|
ATE413188T1
(de)
|
1999-02-05 |
2008-11-15 |
Merck & Co Inc |
Menschliche papillomavirus impfstoff- formulierungen
|
|
EP1046651A1
(de)
*
|
1999-04-19 |
2000-10-25 |
Koninklijke Universiteit Nijmegen |
Zusammensetzungen und Verfahren zur Modulierung des interaktion zwischen dendritischer und T-zellen
|
|
GB9930359D0
(en)
*
|
1999-12-22 |
2000-02-09 |
Glaxo Group Ltd |
Novel polypeptides
|
|
AU780395B2
(en)
*
|
2000-02-01 |
2005-03-17 |
Austin Research Institute, The |
Mucin-1 derived antigens and their use in immunotherapy
|
|
WO2001057068A1
(en)
*
|
2000-02-01 |
2001-08-09 |
The Austin Research Institute |
Mucin-1 derived antigens and their use in immunotherapy
|
|
US6956119B2
(en)
*
|
2000-03-21 |
2005-10-18 |
Hans Loibner |
Polysaccharide-polypeptide conjugate
|
|
AU2001263653B2
(en)
*
|
2000-06-06 |
2006-06-29 |
Igavax Pty Ltd |
Vaccine
|
|
AUPQ797700A0
(en)
|
2000-06-06 |
2000-06-29 |
Austin Research Institute, The |
Vaccine
|
|
US7323174B1
(en)
|
2000-06-12 |
2008-01-29 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Modulation of immune response and methods based thereon
|
|
US20030232055A1
(en)
*
|
2000-07-31 |
2003-12-18 |
Ruslan Medzhitov |
Innate immune system-directed vaccines
|
|
US7754676B2
(en)
*
|
2000-09-15 |
2010-07-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Defensin-antigen fusion proteins
|
|
US7897152B2
(en)
*
|
2000-09-18 |
2011-03-01 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Viral chemokine-antigen fusion proteins
|
|
US20030175287A1
(en)
*
|
2001-01-03 |
2003-09-18 |
Yale University |
Innate immune system-directed vaccines
|
|
GB0112126D0
(en)
|
2001-05-18 |
2001-07-11 |
Allergene Inc |
Composition
|
|
TW200303759A
(en)
*
|
2001-11-27 |
2003-09-16 |
Schering Corp |
Methods for treating cancer
|
|
EP1585960A2
(de)
*
|
2002-01-14 |
2005-10-19 |
Vertex Pharmaceuticals Incorporated |
Mucinimmobiliserte chromatographie
|
|
WO2003089450A2
(en)
*
|
2002-04-22 |
2003-10-30 |
Recopharma Ab |
Fusion polypeptides and methods for inhibiting microbial adhesion
|
|
GB0212036D0
(en)
*
|
2002-05-24 |
2002-07-03 |
Glaxo Group Ltd |
Vaccines
|
|
US20060142546A1
(en)
*
|
2002-09-05 |
2006-06-29 |
Franz-Georg Hanisch |
Immunogenic muc1 glycopeptides
|
|
GB0304634D0
(en)
*
|
2003-02-28 |
2003-04-02 |
Glaxo Group Ltd |
Vaccines
|
|
EP1642905B1
(de)
|
2004-10-02 |
2009-01-21 |
Immatics Biotechnologies GmbH |
Immunogene T-Helfer Epitope von menschlichen Tumorantigenen und deren Verwendung in immunotherapeutischen Methoden
|
|
EP1848804B1
(de)
*
|
2005-01-28 |
2011-10-05 |
Ramot at Tel Aviv University, Ltd. |
Anti-muc1-alpha-beta-antikörper
|
|
MX2007013725A
(es)
|
2005-05-05 |
2008-04-09 |
Sensient Flavors Inc |
Produccion de beta-glucanos y mananos.
|
|
EP1917041A4
(de)
|
2005-08-24 |
2010-09-29 |
Cedars Sinai Medical Center |
Verwendung von fruktosebasierten therapien zur krebsbehandlung
|
|
SI1760089T1
(sl)
|
2005-09-05 |
2009-12-31 |
Immatics Biotechnologies Gmbh |
S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
|
|
DE602005020046D1
(de)
|
2005-09-05 |
2010-04-29 |
Immatics Biotechnologies Gmbh |
Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
|
|
GB2430881B
(en)
|
2005-10-06 |
2010-10-13 |
Ntnu Technology Transfer As |
Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity
|
|
WO2007087420A2
(en)
*
|
2006-01-23 |
2007-08-02 |
Recopharma Ab |
Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
|
|
US20090181041A1
(en)
*
|
2006-01-23 |
2009-07-16 |
Jan Holgersson |
Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
|
|
ES2555544T3
(es)
*
|
2006-03-07 |
2016-01-04 |
Vaxinnate Corporation |
Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
|
|
US20080031872A1
(en)
*
|
2006-08-02 |
2008-02-07 |
Karp Nelson M |
HIV immunogenic composition and method of administration
|
|
US20100247570A1
(en)
*
|
2006-11-13 |
2010-09-30 |
Procell Corporation |
High Mannose Glycoprotein Epitopes
|
|
GB0707096D0
(en)
|
2007-04-12 |
2007-05-23 |
Ntnu Technology Transfer As |
Method
|
|
HUE025636T2
(en)
|
2007-07-27 |
2016-04-28 |
Immatics Biotechnologies Gmbh |
Novel immunogenic epitopes for immunotherapy
|
|
NZ582823A
(en)
|
2007-07-27 |
2012-04-27 |
Immatics Biotechnologies Gmbh |
Composition of tumour-associated peptides and related anti-cancer vaccine
|
|
RS54204B1
(sr)
|
2007-07-27 |
2015-12-31 |
Immatics Biotechnologies Gmbh |
Nova imunoterapija protiv tumora mozga
|
|
US8501907B2
(en)
|
2007-08-10 |
2013-08-06 |
Janssen Biotech, Inc. |
Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
|
|
EP2188306B1
(de)
*
|
2007-08-10 |
2016-06-29 |
Janssen Biotech, Inc. |
Immunoglobulinspaltfragmente als krankheitsindikatoren und zusammensetzungen zum nachweis und zur bindung davon
|
|
RU2527894C2
(ru)
|
2007-11-27 |
2014-09-10 |
Альгифарма ИПР АС |
Использование альгинатных олигомеров в борьбе с биопленками
|
|
ME02267B
(de)
|
2008-03-27 |
2016-04-28 |
Immatics Biotechnologies Gmbh |
Neuartige Immuntherapie gegen Nerven- und Hirntumore
|
|
EP2113253B1
(de)
|
2008-04-30 |
2010-03-31 |
Immatics Biotechnologies GmbH |
Neuartige Formulierungen von Tumor-assoziierten Peptiden, welche an menschliche Leukozytenantigene der Klasse I oder II für Impfungen binden
|
|
PT2119726E
(pt)
|
2008-05-14 |
2015-03-30 |
Immatics Biotechnologies Gmbh |
Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
|
|
WO2010030167A2
(en)
|
2008-09-12 |
2010-03-18 |
Cancer Research Initiative Foundation |
Method of detection and diagnosis of oral and nasopharyngeal cancers
|
|
ES2536465T3
(es)
|
2008-10-01 |
2015-05-25 |
Immatics Biotechnologies Gmbh |
Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
|
|
GB0904942D0
(en)
|
2009-03-23 |
2009-05-06 |
Ntnu Technology Transfer As |
Composition
|
|
GB0904941D0
(en)
|
2009-03-23 |
2009-05-06 |
Ntnu Technology Transfer As |
Composition
|
|
RU2582938C2
(ru)
|
2009-06-03 |
2016-04-27 |
АльгиФарма АС |
Альгинатные олигомеры для применения в преодолении множественной лекарственной устойчивости у бактерий
|
|
EP2330122A1
(de)
|
2009-12-02 |
2011-06-08 |
Asklepios Kliniken Hamburg Gmbh |
OFA/iLRP-abgeleitetes modifiziertes Peptid
|
|
US9023802B2
(en)
|
2009-12-14 |
2015-05-05 |
Immatics Biotechnologies Gmbh |
HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
|
|
GB201004575D0
(en)
|
2010-03-19 |
2010-05-05 |
Immatics Biotechnologies Gmbh |
Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
|
|
GB201004551D0
(en)
|
2010-03-19 |
2010-05-05 |
Immatics Biotechnologies Gmbh |
NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
|
|
GB201019331D0
(en)
|
2010-03-19 |
2010-12-29 |
Immatics Biotechnologies Gmbh |
Methods for the diagnosis and treatment of cancer based on AVL9
|
|
RU2578420C2
(ru)
|
2010-05-10 |
2016-03-27 |
Эсенд Байофармасьютикалз Пти Лтд |
Иммуностимулирующие и вакцинные композиции
|
|
GB201009222D0
(en)
|
2010-06-02 |
2010-07-21 |
Immatics Biotechnologies Gmbh |
Improved cancer therapy based on tumour associated antigens derived from cyclin D1
|
|
GB201015765D0
(en)
|
2010-09-21 |
2010-10-27 |
Immatics Biotechnologies Gmbh |
Use of myeloid cell biomarkers for the diagnosis of cancer
|
|
GB201021289D0
(en)
|
2010-12-15 |
2011-01-26 |
Immatics Biotechnologies Gmbh |
Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
|
|
SG191154A1
(en)
|
2010-12-14 |
2013-07-31 |
Immatics Biotechnologies Gmbh |
Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
|
|
WO2013067597A1
(en)
*
|
2011-11-09 |
2013-05-16 |
Ascend Biopharmaceuticals Pty Ltd |
Immunomodulatory conjugates
|
|
TWI714869B
(zh)
|
2013-08-05 |
2021-01-01 |
德商伊瑪提克斯生物科技有限公司 |
新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物
|
|
GB201319446D0
(en)
|
2013-11-04 |
2013-12-18 |
Immatics Biotechnologies Gmbh |
Personalized immunotherapy against several neuronal and brain tumors
|
|
EP3572510B1
(de)
|
2013-11-21 |
2022-09-21 |
Repertoire Genesis Incorporation |
Analysesystem für t-zellrezeptor- und b-zellrezeptorrepertoir und seine verwendung zur behandlung und diagnose
|
|
EP2883550A1
(de)
|
2013-12-12 |
2015-06-17 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Neuartige promiskuitive, HPV16-abgeleitete T-Helferepitope zur Immuntherapie
|
|
WO2015119180A1
(ja)
*
|
2014-02-06 |
2015-08-13 |
医化学創薬株式会社 |
ムチン4(muc4)糖ペプチドに対する抗体及びその用途
|
|
GB201408255D0
(en)
|
2014-05-09 |
2014-06-25 |
Immatics Biotechnologies Gmbh |
Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
|
|
GB201411037D0
(en)
|
2014-06-20 |
2014-08-06 |
Immatics Biotechnologies Gmbh |
Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
|
|
GB201501017D0
(en)
|
2014-12-23 |
2015-03-04 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
|
|
MA50819A
(fr)
|
2014-12-23 |
2021-04-07 |
Immatics Biotechnologies Gmbh |
Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
|
|
IL301919A
(en)
|
2015-03-27 |
2023-06-01 |
Immatics Biotechnologies Gmbh |
Innovative peptides and a combination of peptides for use in immunotherapy against various tumors
|
|
GB201505585D0
(en)
|
2015-03-31 |
2015-05-13 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
|
|
GB201507030D0
(en)
|
2015-04-24 |
2015-06-10 |
Immatics Biotechnologies Gmbh |
Immunotherapy against lung cancers, in particular NSCLC
|
|
GB201507719D0
(en)
|
2015-05-06 |
2015-06-17 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
|
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
|
IL308735A
(en)
|
2015-07-01 |
2024-01-01 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
|
PT3319985T
(pt)
|
2015-07-06 |
2021-01-06 |
Immatics Biotechnologies Gmbh |
Novos péptidos e combinação de péptidos para uso em imunoterapia do cancro do esófago e outros cancros
|
|
GB201513921D0
(en)
|
2015-08-05 |
2015-09-23 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
|
|
GB201522667D0
(en)
|
2015-12-22 |
2016-02-03 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
|
|
GB201602918D0
(en)
|
2016-02-19 |
2016-04-06 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
|
|
PE20181583A1
(es)
|
2016-03-01 |
2018-10-04 |
Immatics Biotechnologies Gmbh |
Peptido recombinante derivado de la proteina duoxa2
|
|
GB201603987D0
(en)
|
2016-03-08 |
2016-04-20 |
Immatics Biotechnologies Gmbh |
Uterine cancer treatments
|
|
SG10202110335PA
(en)
|
2016-04-06 |
2021-10-28 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
|
|
TW202304970A
(zh)
|
2016-08-26 |
2023-02-01 |
德商英麥提克生物技術股份有限公司 |
用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
|
|
WO2018138257A1
(en)
|
2017-01-27 |
2018-08-02 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
|
TW201841934A
(zh)
|
2017-04-10 |
2018-12-01 |
德商英麥提克生物技術股份有限公司 |
用於治療癌症免疫治療的新穎肽及其肽組合物
|
|
CR20210160A
(es)
|
2017-04-10 |
2021-04-26 |
Immatics Biotechnologies Gmbh |
Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer (divisional de solicitud 2019-0508)
|
|
TW201841937A
(zh)
|
2017-04-10 |
2018-12-01 |
德商英麥提克生物技術股份有限公司 |
用於白血病和其他癌症免疫治療的新穎肽和肽組合物
|
|
WO2019007974A1
(en)
|
2017-07-07 |
2019-01-10 |
Immatics Biotechnologies Gmbh |
NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
|
|
KR20200026898A
(ko)
|
2017-07-07 |
2020-03-11 |
이매틱스 바이오테크놀로지스 게엠베하 |
Nsclc, sclc 등 폐암 및 기타 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
|
|
DE102018107224A1
(de)
|
2018-02-21 |
2019-08-22 |
Immatics Biotechnologies Gmbh |
Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
|
TW202016131A
(zh)
|
2018-05-16 |
2020-05-01 |
德商英麥提克生物技術股份有限公司 |
用於抗癌免疫治療的肽
|
|
US10925947B2
(en)
|
2018-06-29 |
2021-02-23 |
Immatics Biotechnologies Gmbh |
A*03 restricted peptides for use in immunotherapy against cancers and related methods
|
|
TW202019955A
(zh)
|
2018-07-31 |
2020-06-01 |
德商英麥提克生物技術股份有限公司 |
B*07 限制肽和肽組合的抗癌免疫治療和相關方法
|
|
US11945850B2
(en)
|
2018-09-17 |
2024-04-02 |
Immatics Biotechnologies Gmbh |
B*44 restricted peptides for use in immunotherapy against cancers and related methods
|
|
TW202024121A
(zh)
|
2018-09-18 |
2020-07-01 |
德商英麥提克生物技術股份有限公司 |
A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
|
|
TW202039535A
(zh)
|
2018-12-18 |
2020-11-01 |
德商英麥提克生物技術股份有限公司 |
B*08限制肽和肽組合物抗癌免疫治療和相關方法
|
|
EP4021493A1
(de)
|
2019-08-29 |
2022-07-06 |
Eberhard Karls Universität Tübingen, Medizinische Fakultät |
T-zell-epitope von hcmv und verwendungen davon
|
|
EP3892297A1
(de)
|
2020-04-09 |
2021-10-13 |
Eberhard Karls Universität Tübingen Medizinische Fakultät |
Peptide und kombinationen von peptiden zur verwendung in der immuntherapie gegen eine infektion durch sars-cov-2 (covid-19)
|
|
EP3907284A1
(de)
|
2020-05-06 |
2021-11-10 |
Eberhard Karls Universität Tübingen Medizinische Fakultät |
Peptide und kombinationen aus peptiden zur verwendung in der immuntherapie gegen hämatologische neoplasmen und andere krebsarten
|
|
EP3950705A1
(de)
|
2020-08-07 |
2022-02-09 |
Eberhard Karls Universität Tübingen Medizinische Fakultät |
Peptide und kombinationen von peptiden zur verwendung in der immuntherapie gegen eine infektion durch sars-cov-2 (covid-19)
|
|
DE102020125457A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
|
DE102020125465A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
|
TW202229312A
(zh)
|
2020-09-29 |
2022-08-01 |
德商英麥提克生物技術股份有限公司 |
由非hla-a*02顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
|
|
TW202241925A
(zh)
|
2021-01-15 |
2022-11-01 |
德商英麥提克生物技術股份有限公司 |
用於不同類型癌症免疫治療的hla展示肽
|
|
US20240285740A1
(en)
|
2021-05-12 |
2024-08-29 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating cancer
|
|
CN117999350A
(zh)
|
2021-06-25 |
2024-05-07 |
组库创世纪株式会社 |
一种t细胞表位序列的鉴定方法及其应用
|
|
AU2022307659A1
(en)
|
2021-07-05 |
2024-01-25 |
Regeneron Pharmaceuticals, Inc. |
Utilization of antibodies to shape antibody responses to an antigen
|
|
EP4198052A1
(de)
|
2021-12-15 |
2023-06-21 |
Eberhard Karls Universität Tübingen Medizinische Fakultät |
Peptide und antigenbindende proteine zur verwendung in der immuntherapie gegen fibrolamellares hepatozelluläres karzinom (fl-hcc) und andere krebsarten
|
|
EP4311834A1
(de)
|
2022-07-29 |
2024-01-31 |
Eberhard Karls Universität Tübingen, Medizinische Fakultät |
Peptide und kombinationen von peptiden zur verwendung in der immuntherapie gegen oropharyngeale plattenepithelkarzinome und andere krebsarten
|
|
EP4368189A1
(de)
|
2022-11-09 |
2024-05-15 |
Eberhard Karls Universität Tübingen, Medizinische Fakultät |
Peptide und kombinationen aus peptiden zur verwendung in der immuntherapie gegen akute myeloische leukämie (aml) und andere hämatologische neoplasmen
|
|
EP4648790A1
(de)
|
2023-01-12 |
2025-11-19 |
Regeneron Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur gezielten freisetzung von tgfbeta
|
|
EP4761754A2
(de)
|
2023-08-18 |
2026-06-24 |
Immatics Biotechnologies GmbH |
Mhc-anzeigepeptide zur verwendung in der immuntherapie gegen krebs verschiedener art
|
|
KR20260074976A
(ko)
|
2023-09-19 |
2026-05-27 |
리제너론 파마슈티칼스 인코포레이티드 |
바이러스 펩티드 및 이의 용도
|
|
CN122438694A
(zh)
|
2023-12-19 |
2026-07-21 |
瑞泽恩制药公司 |
Foxp3肽及其用途
|
|
WO2025178991A1
(en)
|
2024-02-21 |
2025-08-28 |
Regeneron Pharmaceuticals, Inc. |
Splicing factor gene mutation-associated neoantigenic peptides and uses thereof
|
|
WO2026030428A2
(en)
|
2024-08-01 |
2026-02-05 |
Regeneron Pharmaceuticals, Inc. |
Prostate-specific antigen peptides and uses thereof
|